CA3215723A1 - Diagnostic methods of prostate cancer - Google Patents
Diagnostic methods of prostate cancer Download PDFInfo
- Publication number
- CA3215723A1 CA3215723A1 CA3215723A CA3215723A CA3215723A1 CA 3215723 A1 CA3215723 A1 CA 3215723A1 CA 3215723 A CA3215723 A CA 3215723A CA 3215723 A CA3215723 A CA 3215723A CA 3215723 A1 CA3215723 A1 CA 3215723A1
- Authority
- CA
- Canada
- Prior art keywords
- psma
- radioligand
- pet
- imaging agent
- imaging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/121—Solutions, i.e. homogeneous liquid formulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21305432 | 2021-04-02 | ||
| EP21305432.3 | 2021-04-02 | ||
| PCT/EP2022/058754 WO2022207906A1 (en) | 2021-04-02 | 2022-04-01 | Diagnostic methods of prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3215723A1 true CA3215723A1 (en) | 2022-10-06 |
Family
ID=75588163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3215723A Pending CA3215723A1 (en) | 2021-04-02 | 2022-04-01 | Diagnostic methods of prostate cancer |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240181092A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4313175A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024514293A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230165761A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117120100A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3215723A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL307381A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202304531A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022207906A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3972627A4 (en) | 2019-05-20 | 2023-06-21 | Endocyte, Inc. | Methods for preparing psma conjugates |
| WO2022106629A1 (en) | 2020-11-19 | 2022-05-27 | Novartis Ag | Synthesis of prostate specific membrane antigen (psma) ligands |
| CN120897762A (zh) * | 2023-04-12 | 2025-11-04 | 康奈尔大学 | 用于治疗癌症的放射治疗缀合物 |
| WO2026027442A1 (en) | 2024-08-01 | 2026-02-05 | Novartis Ag | Synthesis of a precursor of radiopharmaceutical products |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013173630A1 (en) * | 2012-05-16 | 2013-11-21 | Cancer Targeted Technology, Llc | Formulation of radiopharmaceuticals containing multiple acidic groups |
| WO2013173583A1 (en) | 2012-05-16 | 2013-11-21 | Cancer Targeted Technology, Llc | Psma inhibitors |
| SMT202300035T1 (it) * | 2013-03-15 | 2023-05-12 | Cancer Targeted Tech Llc | Metodi per preparare agenti di pet imaging marcati con 18f indirizzati al psma e metodi diagnostici con gli stessi |
| KR20240027896A (ko) * | 2017-07-28 | 2024-03-04 | 테크니쉐 우니베르지테트 뮌헨 | 이중 모드 방사성 트레이서 및 치료법 |
-
2022
- 2022-04-01 CA CA3215723A patent/CA3215723A1/en active Pending
- 2022-04-01 WO PCT/EP2022/058754 patent/WO2022207906A1/en not_active Ceased
- 2022-04-01 KR KR1020237032903A patent/KR20230165761A/ko active Pending
- 2022-04-01 IL IL307381A patent/IL307381A/en unknown
- 2022-04-01 EP EP22720606.7A patent/EP4313175A1/en active Pending
- 2022-04-01 JP JP2023560269A patent/JP2024514293A/ja active Pending
- 2022-04-01 TW TW111112920A patent/TW202304531A/zh unknown
- 2022-04-01 CN CN202280026305.2A patent/CN117120100A/zh active Pending
- 2022-04-01 US US18/552,760 patent/US20240181092A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202304531A (zh) | 2023-02-01 |
| CN117120100A (zh) | 2023-11-24 |
| JP2024514293A (ja) | 2024-04-01 |
| WO2022207906A1 (en) | 2022-10-06 |
| IL307381A (en) | 2023-11-01 |
| KR20230165761A (ko) | 2023-12-05 |
| EP4313175A1 (en) | 2024-02-07 |
| US20240181092A1 (en) | 2024-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4313175A1 (en) | Diagnostic methods of prostate cancer | |
| Bhattacharyya et al. | Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas | |
| US20250025584A1 (en) | Radiopharmaceutical treatment methods and use | |
| La et al. | Progress of coordination and utilization of zirconium-89 for positron emission tomography (PET) studies | |
| Ilem-Ozdemir et al. | Nuclear medicine and radiopharmaceuticals for molecular diagnosis | |
| Higuchi et al. | Norepinephrine transporter–targeted cancer theranostics—new horizons | |
| US20250269073A1 (en) | [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof | |
| RU2702294C1 (ru) | Способ радионуклидной диагностики операбельного рака молочной железы с гиперэкспрессией Her2/neu | |
| Vernekar et al. | Radiopharmaceuticals: a new vista for diagnosis and treatment of thyroid cancer | |
| Torres et al. | State of the art and future perspectives of new radinuclides in Nuclear Medicine: Part III | |
| Ruangma et al. | PSMA for PET imaging of prostate cancer | |
| AU2018381046B2 (en) | Radiolabeled progastrin in cancer diagnosis | |
| Rudd | Looking backward to move forward: A chemist’s perspective on the future of radiopharmaceuticals | |
| US20240042067A1 (en) | [177lu] lutetium-psma i&t composition, kit, method of making, and method of using thereof | |
| Young | Imaging and therapeutic radiotracers for prostate cancer | |
| US20250032651A1 (en) | [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof | |
| Lucignani | Non-standard PET radionuclides: time to get ready for new clinical PET strategies | |
| Bailey | Advancing targeting radiopharmaceuticals for theranostic applications | |
| Elison et al. | ANZSNM ASM 2021 POSTER PRESENTATIONS | |
| PART | growth factor (anti-VEGF), antiepidermal growth | |
| WO2026019453A1 (en) | [177lu]lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof | |
| Pascoe et al. | Clinical Applications of Nuclear Medicine | |
| Rose et al. | Imaging with radionuclides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241224 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241224 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241224 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260317 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260317 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260327 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260327 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260408 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260408 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260408 |